Alternatively, as these (rare) genetic variants are numerous, and presumed to alter protein function, we postulate that PON expression and/or activity (encapsulating not only genetic but also environmental influences) might be an interesting target for further exploration, i.e., PON2 as a possible biomarker in patients with MASLD-associated liver fibrosis. This evidence concerns the gene PON2 and metabolic dysfunction-associated steatotic liver disease.